|
|||||
|
|
HER2-low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis |
|
| Authors: | Mingxi Lin PhD Ting Luo PhD Yizi Jin PhD Xiaorong Zhong PhD Dan Zheng PhD Cheng Zeng MM Qing Guo MM Jiong Wu PhD Zhi-Ming Shao PhD Xichun Hu PhD Wentao Yang PhD Jian Zhang PhD |
| Affiliation: | 1. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;2. Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China Multi-Omics Laboratory of Breast Diseases, State Key Laboratory of Biotherapy, National Collaborative, Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China;3. Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China;4. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China Key Laboratory of Breast Cancer in Shanghai, Shanghai, China |
| Abstract: | |
| Keywords: | biopsy breast cancer HER2-low heterogeneity human epidermal growth factor receptor 2 (HER2) prognosis |